促红细胞生成素用于急性心肌梗死的临床观察

目的 探讨重组型促红细胞生成素(rh-EPO)对改善急性心肌梗死(AMI)患者心功能的作用.方法48例符合诊断标准、接受静脉溶栓治疗且溶检成功的首次AMI患者随机分为两组,治疗组在溶栓后即给予rh-EPO 2000 U/次,每周3次,共治疗4周.期间测定肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)峰值浓度,采用Hindmen修正的12导联QRs积分系统估算梗死面积(S),第4周末测定左心室舒张末内径(LVEDd)和左心室射血分数(LVEF),并与对照组比较,同时观察rh-EPO治疗期间不良反应的发生情况.结果治疗组反映梗死严重程度的CK、CK-MB和梗死面积均较对照组明显减轻,差异有统计学意义(均P<0.05);在rh-EPO治疗4周后,反映心功能的LVEDd和LVEF在治疗组也有改善趋势,但两组差异无统计学意义.结论 rh-EPO治疗AMI能有效保护缺血和梗死心肌,明显减轻梗死程度,并可在一定程度上改善心功能.

Clinical study on administration of erythropoietin in patients with acute myocardial infarction

Objective To study the effect of erythropoietin on cardiac function of the patients with acute mycardial infarction (AMI). Methods 48 patients with AMI successfully treated with thrombolytic therapy were randomized into two group,2000 units of recombinant human erytfu-opoietin(rh-EPO) were administrated once a time in therapeutic group,3 times on alternate days in one week and total for 4 weeks. The peak value of serum creatine kinase(CK) and creatinkinase isozyme MB (CK-MB)were measured, myocardial infarct size (S) was estimated by Hindmen's QRS scoring system, and the diameter of left ventricular end diastolic(LVEDd) and left ventricular injection fraction (LVEF) were determined with echocardiography at the 4th weekend in both groups. Results CK, CKMB and S in therapeutic group were lower than in control group (P < 0.05). LVEDd and LVEF were also improved in the therapeutic group. Conclusion rh-EPO can significantly lessen the size of isehemia and infarct myocardium, mitigate the infarction degree and improve the cardiac function slightly in AMI patients.